A double-blind,cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results

Abstract

We enrolled 25 patients with relapsing-remitting or relapsing progressive multiple sclerosis (MS) in a randomized placebo-controlled double-blind study of intravenous immunoglobulin G (IVIG). IVIG Iglkg daily for 2 days was administered every 4 weeks for 24 weeks. Seventeen patients completed the whole trial, whereas eight patients discontinued the trial; four during IVIG treatment and four on placebo. Of the 17 patients who completed the trial, II had no exacerbations during IVIG treatment compared with only six on placebo (P=0.05). The total number of exacerbations in the IVIG period was I / and in the placebo period 15 (NS), and the number of severe exacerbations requiring treatment with intravenous methylprednisolone was four during treatment with IVIG and six on placebo (NS). The results suggest that IVIG treatment may be of beneft for prevention of exacerbations in patients with relapsing MS.

Keywords

IgG intravenous immunoglobulins multiple sclerosis multiple sclerosis therapy

Get full access to this article

View all access options for this article.

References

Oger J. , Kastrukoff LF , Li DK , Paty DW ( 1988) Multiple sclerosis: in relapsing patients, immune functions vary with disease activity as assessed by MRI . Neurology 38: 1739 -1744.

Raine CS (1994) The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion . Ann Neurol 36: S61- 72.

Jungi TW et al. (1990) Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes . IClin Exp Immunol 82: 163 -169.

Frank MM , Basta M. , Fries LF (1992) The effect of intravenous immune globulin on complement-dependent immune damage of cells and tissues . Clin Immunol Immunopathol 62: S82-S86.

Anderson UG , Bjork L. , Skansen-Saphir U. , Anderson JP (1993) Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG . Immunol 79: 211-216.

Tenser RB , Hay KA , Aberg JA (1993) Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets . Arch Neurol 50: 417 - 420.

Van Engelen BG et al. (1994) Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis . J Neurol Neurosurg Psychiatry 57(Suppl:) 65-68.

Van Engelen BG et al. (1992) Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis . Ann Neurol 32: 834-835.

Soukop W. , Tschabitscher H. (1986) Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy . Wien Med Wochenschr 136: 477-480.

10.

Rothfelder U. , Neu I. , Pelka R. (1982) Therapy of multiple sclerosis with immunoglobulin G . MMW Munch Med Wochenschr 124: 74 - 78.

11.

Schuller E. , Govaerts A. (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients . Eur Neurol 22: 205-212.

12.

Cook SD et al. (1992) Intravenous gamma globulin in progressive MS . Acta Neurol Scand 86: 171-175.

13.

Achiron A. et al. (1992) Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis . Arch Neurol 49: 1233 -1236.

14.

McFarland HF et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis . Ann Neurol 32: 758 - 766.

15.

Poser CM et al. (1893) New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 13: 227-231.

16.

Sipe JC et al. (1984) A neurologic rating scale (NRS) for use in multiple sclerosis . Neurology 34: 1368-1372.

17.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology 33: 1444-1452.

18.

Maida E. , Schwaighofer B. (1994) Long-term therapy with high-dose IV immunoglobulins in MS. Clinical and MRI observations . Proceedings 10th congress of the European Committee for Treatment and Research in Multiple Sclerosis. Athens p 94.

19.

Achiron A. et al. (1995) Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis - a pilot study . J Neuroimmunol Suppl 1: 56 .

20.

Achiron A. et al. (1995) Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: A randomized, double-blind, multicenter, placebo-controlled trial . J Neuroimmunol Suppl 1: 15 .

21.

Bjoro K. et al. (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin . N Engl J Med 331: 1607 -1611.